Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder

W. Joseph Herring, Timothy E. Wilens, Lenard A. Adler, Christine Baranak, Kenneth Liu, Duane B. Snavely, Christopher R. Lines, David Michelson

Research output: Contribution to journalArticle

Abstract

Background: It has been suggested that the histamine subtype 3 receptor inverse agonists such as MK-0249 might be effective in treating attention-deficit/hyperactivity disorder (ADHD). We evaluated the effects of MK-0249 in adults with ADHD. Method: A randomized, double-blind, placebo-controlled, incomplete block, 2-period crossover study of MK-0249 5-10 mg/d and osmotic-release oral system (OROS) methylphenidate 54-72 mg/d (active comparator) was performed in 72 men and women aged ≥ 18 to ≤ 55 years who met DSM-IV criteria for ADHD of either inattentive or combined subtype and who had a chronic course of behavior disorder. The study was conducted from August 2007 through April 2008 at 6 US sites. Primary efficacy was assessed by the mean change from baseline in the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score after 4 weeks of treatment. Results: Change from baseline in AISRS at week 4 for MK-0249 was not different from placebo (P = .341), whereas a significant benefit was seen for OROS methylphenidate versus placebo (P < .001). Analysis of secondary end points, including the Conners Adult ADHD Rating Scales, showed results consistent with the AISRS. A similar percentage of patients reported adverse events for MK-0249 compared with placebo (73% versus 69%, respectively). However, a greater percentage of patients reported insomnia as an adverse event with MK-0249 treatment compared with placebo (32% versus 11%, respectively). Conclusions: MK-0249 10 mg/d is not effective for the treatment of adult ADHD. Trial Registration: ClinicalTrials.gov identifier: NCT00475735

Original languageEnglish (US)
JournalJournal of Clinical Psychiatry
Volume73
Issue number7
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Histamine Agonists
Attention Deficit Disorder with Hyperactivity
Placebos
Methylphenidate
Research Personnel
Sleep Initiation and Maintenance Disorders
MK-0249
Mental Disorders
Diagnostic and Statistical Manual of Mental Disorders
Cross-Over Studies
Histamine
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder. / Herring, W. Joseph; Wilens, Timothy E.; Adler, Lenard A.; Baranak, Christine; Liu, Kenneth; Snavely, Duane B.; Lines, Christopher R.; Michelson, David.

In: Journal of Clinical Psychiatry, Vol. 73, No. 7, 2012.

Research output: Contribution to journalArticle

Herring, W. Joseph ; Wilens, Timothy E. ; Adler, Lenard A. ; Baranak, Christine ; Liu, Kenneth ; Snavely, Duane B. ; Lines, Christopher R. ; Michelson, David. / Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder. In: Journal of Clinical Psychiatry. 2012 ; Vol. 73, No. 7.
@article{527d1f4d41aa40f3853597f716f36146,
title = "Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder",
abstract = "Background: It has been suggested that the histamine subtype 3 receptor inverse agonists such as MK-0249 might be effective in treating attention-deficit/hyperactivity disorder (ADHD). We evaluated the effects of MK-0249 in adults with ADHD. Method: A randomized, double-blind, placebo-controlled, incomplete block, 2-period crossover study of MK-0249 5-10 mg/d and osmotic-release oral system (OROS) methylphenidate 54-72 mg/d (active comparator) was performed in 72 men and women aged ≥ 18 to ≤ 55 years who met DSM-IV criteria for ADHD of either inattentive or combined subtype and who had a chronic course of behavior disorder. The study was conducted from August 2007 through April 2008 at 6 US sites. Primary efficacy was assessed by the mean change from baseline in the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score after 4 weeks of treatment. Results: Change from baseline in AISRS at week 4 for MK-0249 was not different from placebo (P = .341), whereas a significant benefit was seen for OROS methylphenidate versus placebo (P < .001). Analysis of secondary end points, including the Conners Adult ADHD Rating Scales, showed results consistent with the AISRS. A similar percentage of patients reported adverse events for MK-0249 compared with placebo (73{\%} versus 69{\%}, respectively). However, a greater percentage of patients reported insomnia as an adverse event with MK-0249 treatment compared with placebo (32{\%} versus 11{\%}, respectively). Conclusions: MK-0249 10 mg/d is not effective for the treatment of adult ADHD. Trial Registration: ClinicalTrials.gov identifier: NCT00475735",
author = "Herring, {W. Joseph} and Wilens, {Timothy E.} and Adler, {Lenard A.} and Christine Baranak and Kenneth Liu and Snavely, {Duane B.} and Lines, {Christopher R.} and David Michelson",
year = "2012",
doi = "10.4088/JCP.11m07178",
language = "English (US)",
volume = "73",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "7",

}

TY - JOUR

T1 - Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder

AU - Herring, W. Joseph

AU - Wilens, Timothy E.

AU - Adler, Lenard A.

AU - Baranak, Christine

AU - Liu, Kenneth

AU - Snavely, Duane B.

AU - Lines, Christopher R.

AU - Michelson, David

PY - 2012

Y1 - 2012

N2 - Background: It has been suggested that the histamine subtype 3 receptor inverse agonists such as MK-0249 might be effective in treating attention-deficit/hyperactivity disorder (ADHD). We evaluated the effects of MK-0249 in adults with ADHD. Method: A randomized, double-blind, placebo-controlled, incomplete block, 2-period crossover study of MK-0249 5-10 mg/d and osmotic-release oral system (OROS) methylphenidate 54-72 mg/d (active comparator) was performed in 72 men and women aged ≥ 18 to ≤ 55 years who met DSM-IV criteria for ADHD of either inattentive or combined subtype and who had a chronic course of behavior disorder. The study was conducted from August 2007 through April 2008 at 6 US sites. Primary efficacy was assessed by the mean change from baseline in the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score after 4 weeks of treatment. Results: Change from baseline in AISRS at week 4 for MK-0249 was not different from placebo (P = .341), whereas a significant benefit was seen for OROS methylphenidate versus placebo (P < .001). Analysis of secondary end points, including the Conners Adult ADHD Rating Scales, showed results consistent with the AISRS. A similar percentage of patients reported adverse events for MK-0249 compared with placebo (73% versus 69%, respectively). However, a greater percentage of patients reported insomnia as an adverse event with MK-0249 treatment compared with placebo (32% versus 11%, respectively). Conclusions: MK-0249 10 mg/d is not effective for the treatment of adult ADHD. Trial Registration: ClinicalTrials.gov identifier: NCT00475735

AB - Background: It has been suggested that the histamine subtype 3 receptor inverse agonists such as MK-0249 might be effective in treating attention-deficit/hyperactivity disorder (ADHD). We evaluated the effects of MK-0249 in adults with ADHD. Method: A randomized, double-blind, placebo-controlled, incomplete block, 2-period crossover study of MK-0249 5-10 mg/d and osmotic-release oral system (OROS) methylphenidate 54-72 mg/d (active comparator) was performed in 72 men and women aged ≥ 18 to ≤ 55 years who met DSM-IV criteria for ADHD of either inattentive or combined subtype and who had a chronic course of behavior disorder. The study was conducted from August 2007 through April 2008 at 6 US sites. Primary efficacy was assessed by the mean change from baseline in the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score after 4 weeks of treatment. Results: Change from baseline in AISRS at week 4 for MK-0249 was not different from placebo (P = .341), whereas a significant benefit was seen for OROS methylphenidate versus placebo (P < .001). Analysis of secondary end points, including the Conners Adult ADHD Rating Scales, showed results consistent with the AISRS. A similar percentage of patients reported adverse events for MK-0249 compared with placebo (73% versus 69%, respectively). However, a greater percentage of patients reported insomnia as an adverse event with MK-0249 treatment compared with placebo (32% versus 11%, respectively). Conclusions: MK-0249 10 mg/d is not effective for the treatment of adult ADHD. Trial Registration: ClinicalTrials.gov identifier: NCT00475735

UR - http://www.scopus.com/inward/record.url?scp=84864413866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864413866&partnerID=8YFLogxK

U2 - 10.4088/JCP.11m07178

DO - 10.4088/JCP.11m07178

M3 - Article

VL - 73

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 7

ER -